SMARCA1

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 1 · P28370 · SMARCA1 on Sugi Atlas →

0 patent compounds predicted against SMARCA1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SMARCA1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE2RECRUITING
An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA) PHASE1/PHASE2COMPLETED
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. PHASE2NOT_YET_RECRUITING
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
Newborn Screening for Spinal Muscular Atrophy nanCOMPLETED
Natural History Study of Smith-Magenis Syndrome nanACTIVE_NOT_RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Palliative Care in Spinal Muscular Atrophy (SMA) 1 nanCOMPLETED
Motor Development and Orthoses in Spinal Muscular Atrophy (SMA) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SMARCA1 binder may also engage these)

ProteinNameSimilarity
Q91ZW3 1.000 Q91ZW3 →
SMARCA5 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5 1.000 landscape →
Q6PGB8 1.000 Q6PGB8 →
Q8RWY3 0.999 Q8RWY3 →
Q7G8Y3 0.998 Q7G8Y3 →
F4JY24 0.998 F4JY24 →
P41877 0.996 P41877 →
D3ZA12 0.994 D3ZA12 →
Q24368 0.994 Q24368 →
A3KFM7 0.994 A3KFM7 →
Q8TD26 0.992 Q8TD26 →
B6ZLK2 0.992 B6ZLK2 →
Q14562 0.992 Q14562 →
P38144 0.991 P38144 →
P40201 0.990 P40201 →
Q7ZU90 0.990 Q7ZU90 →
P32863 0.990 P32863 →
Q9UT24 0.990 Q9UT24 →
P40562 0.989 P40562 →
A9X4T1 0.989 A9X4T1 →
CHD1 Chromodomain-helicase-DNA-binding protein 1 0.989 landscape →
Q5A310 0.989 Q5A310 →
A5E3K3 0.989 A5E3K3 →
Q9S775 0.989 Q9S775 →
Q4TVV3 0.989 Q4TVV3 →
Q6CGD1 0.989 Q6CGD1 →
P32639 0.988 P32639 →
Q9UTP9 0.988 Q9UTP9 →
B0R061 0.988 B0R061 →
Q6FPT7 0.988 Q6FPT7 →